Sökning: id:"swepub:oai:DiVA.org:liu-114250" >
Severe infusion-rel...
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
-
- Norin, Stefan (författare)
- Karolinska Institutet
-
- Bjorkstrand, Bo (författare)
- Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
-
- Rommel, Franz (författare)
- Region Östergötland, Hematologiska kliniken US
-
visa fler...
-
- Timberg, Lars (författare)
- Kristianstad Central Hospital, Sweden
-
- Andersson, Per-Ola (författare)
- Sahlgrens University Hospital, Sweden
-
- Haggstrom, Johan (författare)
- Kalmar Hospital, Sweden
-
- Aldrin, Anders (författare)
- Visby Hospital, Sweden
-
- Hansson, Lotta (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2015
- 2015
- Engelska.
-
Ingår i: Leukemia Research. - : Elsevier. - 0145-2126 .- 1873-5835. ; 39:1, s. 33-37
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- Adverse reaction; Chronic lymphocytic leukemia; Rituximab; Therapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas